

APOE Gene Test Results & Risk Information

This sheet summarizes the APOE Gene Test information provided to you as part of screening for Generation Study 1. It should be attached to the Standardized APOE Risk Information handout used during your visit.


Genetic Testing Result: Your *APOE* gene test result is: **e3/e4**

Risk Information for Mild Cognitive Impairment or Dementia due to Alzheimer's Disease:

Your risk information is based on your APOE result of **e3/e4**.

Your estimated risk through age 85 of developing mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD) is **20%-25%**. This also means that your estimated risk of NOT developing these conditions through age 85 is 75-80%.

Out of 100 individuals with your same APOE result, we would expect 20-25 of them to develop MCI or dementia due to AD through age 85, while 75-80 would not.



It is difficult to give an exact risk, as there are other factors that could increase or decrease risk when estimating an individual's risk for MCI or dementia due to Alzheimer's disease.

Limitations of the risk estimates:

- There is a wide range of information regarding the APOE gene's impact on the risk of Alzheimer's disease; other studies may have reported higher or lower risks related to the APOE gene. The risk information that we provided you is our best estimate at this time and is based on one large study.
- The risk information we are sharing with you is drawn from studies in which the majority of participants were White. We do not know if the risks are similar for all racial and ethnic groups.

Resources:

Please refer to the slide titled "For More Information" in your packet for a list of resources that may provide you with additional information and support.

Questions:

If you have any questions about any of the information presented in this document, please contact:

Langlois CM, Bradbury A, Wood EM, Roberts JS, Kim SYH, Riviere ME, Liu F, Reiman EM, Tariot PN, Karlawish J, Langbaum JB. Alzheimer's Prevention Initiative Generation Program: Development of an *APOE* genetic counseling and disclosure process in the context of clinical trials. *Alzheimer's Dement* (N Y). 2019 Nov 6;5:705-716. doi: 10.1016/j.trci.2019.09.013.

The Generation Program was funded by Novartis and Amgen, in collaboration with the Banner Alzheimer's Institute. Generation Study 1 was supported by funding from the National Institute on Aging (1UF1AG046150), part of the National Institutes of Health, as well as the Alzheimer's Association, FBRI, GHR Foundation and Banner Alzheimer's Foundation.